US Penny Stocks To Watch In January 2025

As the U.S. stock market navigates a landscape marked by the Federal Reserve's decision to keep interest rates steady, investors remain focused on forthcoming big-tech earnings reports. Amid these broader market dynamics, penny stocks continue to capture attention for their potential to offer affordability and growth opportunities. Despite being considered an outdated term, penny stocks—often representing smaller or newer companies—can still be relevant investment options when supported by strong financial fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.69	$11.4M	★★★★★★
BAB (OTCPK:BABB)	$0.8985	$6.25M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$121.65M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.283	$10.58M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.73	$84.93M	★★★★★★
North European Oil Royalty Trust (NYSE:NRT)	$4.57	$42M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$3.11	$52.57M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.29	$23.06M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.90	$79.98M	★★★★★☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Huize Holding (NasdaqGM:HUIZ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Huize Holding Limited operates an online insurance product and service platform in the People's Republic of China, with a market cap of $31.25 million.

Operations: The company generates revenue of CN¥1.20 billion from its insurance brokerage services segment.

Market Cap: $31.25M

Huize Holding Limited, with a market cap of $31.25 million, operates in the online insurance sector and has shown resilience despite challenges. The company reported CN¥1.20 billion in revenue from its insurance brokerage services, indicating substantial operational activity. However, profit margins have declined to 1.7% from 5% last year, highlighting profitability concerns amidst increased volatility and negative earnings growth over the past year. Recent strategic initiatives include launching "PrimeMed," a mid-tier medical insurance product aimed at expanding coverage options in collaboration with industry partners, which may enhance its market positioning despite current financial pressures.

• Dive into the specifics of Huize Holding here with our thorough balance sheet health report.
• Assess Huize Holding's future earnings estimates with our detailed growth reports.

HilleVax (NasdaqGS:HLVX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: HilleVax, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel vaccines in the United States, with a market cap of $93.57 million.

Operations: HilleVax, Inc. currently does not report any revenue segments as it is in the clinical-stage of developing innovative vaccines.

Market Cap: $93.57M

HilleVax, Inc., with a market cap of US$93.57 million, is a clinical-stage biopharmaceutical company that remains pre-revenue as it focuses on developing novel vaccines. Recent executive changes include the departure of key officers, although some will continue in advisory roles. The company reported substantial net losses for the third quarter and nine months ending September 2024, reflecting ongoing financial challenges typical for companies at this stage. Despite being debt-free and having sufficient cash runway to cover liabilities, HilleVax faces hurdles in achieving profitability soon due to its unprofitable status and negative return on equity.

• Click here to discover the nuances of HilleVax with our detailed analytical financial health report.
• Review our growth performance report to gain insights into HilleVax's future.

Ovid Therapeutics (NasdaqGS:OVID)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for epilepsies and seizure-related neurological disorders in the United States, with a market cap of $51.97 million.

Operations: Ovid Therapeutics generates its revenue from the Pharmaceuticals segment, totaling $0.63 million.

Market Cap: $51.97M

Ovid Therapeutics, with a market cap of US$51.97 million, is a pre-revenue biopharmaceutical company focused on epilepsy treatments. Despite its unprofitable status and negative return on equity of -42.6%, Ovid remains debt-free and has short-term assets of US$65.8 million exceeding liabilities, providing some financial stability. However, the company faces challenges with less than a year of cash runway if current free cash flow trends continue to decline. Recent events include being removed from the NASDAQ Biotechnology Index and presenting at the Longwood Healthcare Leaders Summit, highlighting ongoing efforts to engage stakeholders despite financial hurdles.

• Navigate through the intricacies of Ovid Therapeutics with our comprehensive balance sheet health report here.
• Examine Ovid Therapeutics' earnings growth report to understand how analysts expect it to perform.

Make It Happen

• Click here to access our complete index of 709 US Penny Stocks.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com